Bioregulators
Thymalin
Thymalin is not one defined peptide but a mixture: a complex of polypeptides extracted from calf thymus, with pieces up to roughly 10 kDa in size. Two dipeptides, Lys-Glu and Glu-Trp, are named as its active parts.
- Container
- Glass vial, crimp seal, flip-top cap
- Storage
- -20 °C, desiccated
- Paperwork
- Lot certificate (HPLC + mass spec) shown before you pay
Lot certificates
You’ll see American Peptides on the lab’s copy. They’re our supplier.
- 20 mg, lot THYM20-0318: 99.80% purity (RP-HPLC), 18.79 mg measured, identity confirmed by mass spec. Issued 2026-04-03 by Bioviridian Inc.. Verify certificate COA3390
Our vials are filled from lots made by our supplier, American Peptides, and tested by Bioviridian Inc.The laboratory’s original certificate lists American Peptides as the vendor. Look up the code at bioviridians.com to check it.
What researchers study it for
- Maturation of T lymphocytes
- Immune activity during infections
- Studies of add-on use in COVID-19
- Production of inflammatory cytokines
How it is thought to work
Those who developed thymalin acknowledge that its molecular mechanism has yet to be worked out. Two laboratory observations are reported. First, hematopoietic stem cells from humans, grown in culture with the extract, showed less CD44 and CD117 (both stem-cell markers) and more CD28, a pattern the researchers interpret as maturation into T lymphocytes. Second, when peripheral blood mononuclear cells from donors were stimulated with lipopolysaccharide, the extract reduced how much IL-1beta, IL-6 and TNF-alpha they released.
Where the research stands
Registered medicine in Russia (a thymus extract); no FDA approval found. According to one source, Russia has approved thymalin as an immunomodulator since 1982. The COVID-19 trial we read was open-label, run at a single center, and enrolled 92 patients. No FDA label or ClinicalTrials.gov record turned up. These statements concern the registered Russian product, not research-grade material.
Sources
- Khavinson VK, et al. (2020). Thymalin: Activation of Differentiation of Human Hematopoietic Stem Cells. Bulletin of Experimental Biology and Medicine.
- Khavinson VK, et al. (2021). Results and Prospects of Using Activator of Hematopoietic Stem Cell Differentiation in Complex Therapy for Patients with COVID-19. Stem Cell Reviews and Reports.
- Linkova N, et al. (2023). The Influence of KE and EW Dipeptides in the Composition of the Thymalin Drug on Gene Expression and Protein Synthesis Involved in the Pathogenesis of COVID-19. International Journal of Molecular Sciences.
- Avolio F, et al. (2022). Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line. International Journal of Molecular Sciences.
Read more
For laboratory research use only. Not a drug, food, supplement or cosmetic; not for human or veterinary use. Nothing on this page is medical advice or a usage guide.